vs

Side-by-side financial comparison of FVCBankcorp, Inc. (FVCB) and NEKTAR THERAPEUTICS (NKTR). Click either name above to swap in a different company.

NEKTAR THERAPEUTICS is the larger business by last-quarter revenue ($21.8M vs $16.9M, roughly 1.3× FVCBankcorp, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs -25.3%). FVCBankcorp, Inc. produced more free cash flow last quarter ($23.8M vs $-65.0M). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs 0.4%).

FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

FVCB vs NKTR — Head-to-Head

Bigger by revenue
NKTR
NKTR
1.3× larger
NKTR
$21.8M
$16.9M
FVCB
Growing faster (revenue YoY)
FVCB
FVCB
+4402.8% gap
FVCB
4377.5%
-25.3%
NKTR
More free cash flow
FVCB
FVCB
$88.8M more FCF
FVCB
$23.8M
$-65.0M
NKTR
Faster 2-yr revenue CAGR
FVCB
FVCB
Annualised
FVCB
586.6%
0.4%
NKTR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FVCB
FVCB
NKTR
NKTR
Revenue
$16.9M
$21.8M
Net Profit
$-36.1M
Gross Margin
Operating Margin
43.7%
-126.9%
Net Margin
-165.4%
Revenue YoY
4377.5%
-25.3%
Net Profit YoY
-596.9%
EPS (diluted)
$0.31
$-4.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FVCB
FVCB
NKTR
NKTR
Q4 25
$16.9M
$21.8M
Q3 25
$416.0K
$11.8M
Q2 25
$15.8M
$11.2M
Q1 25
$382.0K
$10.5M
Q4 24
$378.0K
$29.2M
Q3 24
$412.0K
$24.1M
Q2 24
$415.0K
$23.5M
Q1 24
$359.0K
$21.6M
Net Profit
FVCB
FVCB
NKTR
NKTR
Q4 25
$-36.1M
Q3 25
$5.6M
$-35.5M
Q2 25
$5.7M
$-41.6M
Q1 25
$5.2M
$-50.9M
Q4 24
$7.3M
Q3 24
$4.7M
$-37.1M
Q2 24
$4.2M
$-52.4M
Q1 24
$1.3M
$-36.8M
Gross Margin
FVCB
FVCB
NKTR
NKTR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
72.7%
Q3 24
81.6%
Q2 24
58.5%
Q1 24
60.6%
Operating Margin
FVCB
FVCB
NKTR
NKTR
Q4 25
43.7%
-126.9%
Q3 25
-268.6%
Q2 25
45.9%
-324.2%
Q1 25
-425.8%
Q4 24
49.2%
Q3 24
-142.4%
Q2 24
-211.9%
Q1 24
-163.7%
Net Margin
FVCB
FVCB
NKTR
NKTR
Q4 25
-165.4%
Q3 25
1341.1%
-301.3%
Q2 25
36.0%
-372.2%
Q1 25
1352.1%
-486.4%
Q4 24
24.9%
Q3 24
1133.3%
-153.6%
Q2 24
1001.2%
-222.9%
Q1 24
373.3%
-170.1%
EPS (diluted)
FVCB
FVCB
NKTR
NKTR
Q4 25
$0.31
$-4.67
Q3 25
$0.31
$-1.87
Q2 25
$0.31
$-2.95
Q1 25
$0.28
$-0.24
Q4 24
$0.27
$-2.07
Q3 24
$0.25
$-2.66
Q2 24
$0.23
$-3.76
Q1 24
$0.07
$-0.19

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FVCB
FVCB
NKTR
NKTR
Cash + ST InvestmentsLiquidity on hand
$15.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$253.6M
$89.8M
Total Assets
$2.3B
$280.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FVCB
FVCB
NKTR
NKTR
Q4 25
$15.1M
Q3 25
$41.0M
Q2 25
$43.0M
Q1 25
$38.9M
Q4 24
$44.3M
Q3 24
$30.1M
Q2 24
$27.9M
Q1 24
$48.6M
Stockholders' Equity
FVCB
FVCB
NKTR
NKTR
Q4 25
$253.6M
$89.8M
Q3 25
$249.8M
$85.1M
Q2 25
$243.2M
$-24.2M
Q1 25
$242.3M
$13.7M
Q4 24
$235.4M
$60.7M
Q3 24
$230.8M
$48.9M
Q2 24
$226.5M
$79.7M
Q1 24
$220.7M
$126.7M
Total Assets
FVCB
FVCB
NKTR
NKTR
Q4 25
$2.3B
$280.4M
Q3 25
$2.3B
$301.3M
Q2 25
$2.2B
$207.5M
Q1 25
$2.2B
$256.2M
Q4 24
$2.2B
$303.9M
Q3 24
$2.3B
$308.0M
Q2 24
$2.3B
$343.3M
Q1 24
$2.2B
$396.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FVCB
FVCB
NKTR
NKTR
Operating Cash FlowLast quarter
$23.9M
$-65.0M
Free Cash FlowOCF − Capex
$23.8M
$-65.0M
FCF MarginFCF / Revenue
140.7%
-298.0%
Capex IntensityCapex / Revenue
0.3%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$40.0M
$-208.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FVCB
FVCB
NKTR
NKTR
Q4 25
$23.9M
$-65.0M
Q3 25
$7.6M
$-48.8M
Q2 25
$3.3M
$-45.7M
Q1 25
$5.4M
$-49.1M
Q4 24
$18.2M
$-46.2M
Q3 24
$4.7M
$-43.9M
Q2 24
$1.6M
$-37.7M
Q1 24
$7.2M
$-47.9M
Free Cash Flow
FVCB
FVCB
NKTR
NKTR
Q4 25
$23.8M
$-65.0M
Q3 25
$7.6M
$-48.9M
Q2 25
$3.3M
$-45.8M
Q1 25
$5.4M
$-49.1M
Q4 24
$18.1M
$-46.6M
Q3 24
$4.6M
$-44.6M
Q2 24
$1.5M
$-37.9M
Q1 24
$7.1M
$-48.0M
FCF Margin
FVCB
FVCB
NKTR
NKTR
Q4 25
140.7%
-298.0%
Q3 25
1818.0%
-414.5%
Q2 25
20.8%
-409.6%
Q1 25
1413.6%
-469.0%
Q4 24
4786.0%
-159.9%
Q3 24
1121.8%
-184.9%
Q2 24
361.2%
-161.3%
Q1 24
1988.3%
-222.0%
Capex Intensity
FVCB
FVCB
NKTR
NKTR
Q4 25
0.3%
0.1%
Q3 25
0.2%
1.0%
Q2 25
0.1%
0.3%
Q1 25
4.2%
0.0%
Q4 24
37.3%
1.6%
Q3 24
14.1%
2.8%
Q2 24
12.8%
0.8%
Q1 24
3.9%
0.7%
Cash Conversion
FVCB
FVCB
NKTR
NKTR
Q4 25
Q3 25
1.36×
Q2 25
0.58×
Q1 25
1.05×
Q4 24
-6.36×
Q3 24
1.00×
Q2 24
0.37×
Q1 24
5.34×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons